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Human metabolic pathway prediction <p>A computation pathway analysis of the human genome is presented that assigns enzymes encoded by the genome to predicted meta- bolic pathways. This analysis provides a genome-based view of human nutrition.</p>
Abstract
Background: We present a computational pathway analysis of the human genome that assigns
enzymes encoded therein to predicted metabolic pathways. Pathway assignments place genes in
their larger biological context, and are a necessary first step toward quantitative modeling of
metabolism.
Results: Our analysis assigns 2,709 human enzymes to 896 bioreactions; 622 of the enzymes are
assigned roles in 135 predicted metabolic pathways. The predicted pathways closely match the
known nutritional requirements of humans. This analysis identifies probable omissions in the human
genome annotation in the form of 203 pathway holes (missing enzymes within the predicted
pathways). We have identified putative genes to fill 25 of these holes. The predicted human
metabolic map is described by a Pathway/Genome Database called HumanCyc, which is available
at http://HumanCyc.org/. We describe the generation of HumanCyc, and present an analysis of the
human metabolic map. For example, we compare the predicted human metabolic pathway
complement to the pathways of Escherichia coli and Arabidopsis thaliana and identify 35 pathways that
are shared among all three organisms.
Conclusions: Our analysis elucidates a significant portion of the human metabolic map, and also
indicates probable unidentified genes in the genome. HumanCyc provides a genome-based view of
human nutrition that associates the essential dietary requirements of humans with a set of
metabolic pathways whose existence is supported by the human genome. The database places
many human genes in a pathway context, thereby facilitating analysis of gene expression,
proteomics, and metabolomics datasets through a publicly available online tool called the Omics
Viewer.
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Background
The human genome is a blueprint, but for what machinery?
One approach to understanding the complex processes
encoded by the human genome is to assign its enzyme prod-
ucts to biochemical pathways that define regulated sequences
of biochemical transformations. Pathway and interaction
assignments place genes in their larger biological context, and
enable causal inferences about the likely effects of mutations,
drug interventions and changes in gene regulation. They are
a first step toward quantitative modeling of metabolism.
Assignment of genes to pathways also permits a validation of
the human genome annotation because patterns of pathway
assignments spotlight likely false-positive and false-negative
genome annotations. For example, false-negative assign-
ments appear as pathway holes: missing enzymes within a
pathway that are likely to be hiding in the genome.
SRI's Bioinformatics Research Group has developed a path-
way-bioinformatics technology called a pathway/genome
database (PGDB), which describes the genome, the proteome,
the reactome and the metabolome of an organism. A PGDB
describes the replicons of an organism (chromosome(s) or
plasmid(s)), its genes, the product of each gene, the biochem-
ical reaction(s), if any, catalyzed by each gene product, the
substrates of each reaction, and the organization of those
reactions into pathways. Pathway Tools is a reusable software
environment for constructing and managing PGDBs [1]. It
supports many operations on PGDBs including PGDB crea-
tion, querying and visualization, analysis, interactive editing,
web publishing, and prediction of the metabolic-pathway
complement of an organism.
The power of Pathway Tools is derived from both its database
schema, and its software components. Both were originally
developed for the EcoCyc project [2,3]. A PGDB can be
thought of as a symbolic computational theory of a species'
metabolic functions and genetic interactions [4], encoding
knowledge in a manner suitable for computational analysis.
Indeed, once an organism's genome and biochemical network
are encoded within the schema of a PGDB, new possibilities
for symbolic computational analysis arise, because many
important semantic relationships are described in a comput-
able fashion.
PathoLogic is one of the Pathway Tools software components.
Its primary function is to generate a new PGDB from an
organism's annotated genome. PathoLogic predicts the meta-
bolic pathways of the organism, providing new global insights
about its biochemistry, and generates reports that summarize
the evidence for the presence of each predicted metabolic
pathway. We used PathoLogic to generate HumanCyc, a
PGDB for Homo sapiens, from the annotated human genome.
The genome data used as input to PathoLogic combined data
from the Ensembl database [5], the LocusLink database [6]
and GenBank [7].
Our analysis assigns 2,709 human enzymes to 135 predicted
metabolic pathways. It provides a genome-based view of
human nutrition that associates the essential dietary require-
ments of humans that were previously derived mainly from
animal and tissue extract studies to a set of metabolic path-
ways whose existence is derived from the human genome.
The analysis also identifies probable omissions in the human-
genome annotation in the form of pathway holes (missing
enzymes within the predicted pathways); we have identified
putative genes to fill some of those pathway holes. This paper
describes the generation of HumanCyc, and presents an anal-
ysis of the human metabolic map. The computationally pre-
dicted pathways are consistent with known human dietary
requirements. We compare the predicted human metabolic
pathway complement to the pathways of Escherichia coli and
Arabidopsis thaliana and identify 35 pathways that are
shared among all three organisms, and therefore define an
upper bound on a potential set of universally occurring meta-
bolic pathways.
Results
Prediction of human metabolic pathways
We applied PathoLogic to the input files containing the H.
sapiens  annotated genome, as described in Materials and
methods, generating HumanCyc.
Table 1 shows the results of PathoLogic's enzyme matching
during the PGDB automated build. This computational
matching process found more than 2,300 matches between
gene products in the annotated genome and reactions in Met-
aCyc. Both the ambiguous matches (row 3 in Table 1) and the
proteins labeled as 'probable enzymes' by PathoLogic (row 5)
were examined manually; about half of them were manually
matched to enzymes, as explained in Materials and methods.
Sometimes one gene product is matched to more than one
reaction, as happens with multifunctional enzymes (for
example, the gene product shown in Figure 1 would be
matched to two different reactions). So the number of
matches is higher than the number of proteins matched. The
'Unmatched' row includes human proteins that are not
enzymes.
A typical description of a gene product's function in Ensembl Figure 1
A typical description of a gene product's function in Ensembl. This example 
aims to communicate to the reader exactly what information was obtained 
from Ensembl; it shows multiple functions, synonyms and EC numbers, as 
well as a Swiss-Prot accession number, all in one line of text. A Perl script 
was developed to parse these descriptions and extract the relevant 
information.
GDH/6PGL ENDOPLASMIC BIFUNCTIONAL PROTEIN PRECURSOR  
[INCLUDES: GLUCOSE 1-DEHYDROGENASE (EC 1.1.1.47)  
(HEXOSE-6-PHOSPHATE DEHYDROGENASE);  
6- PHOSPHOGLUCONOLACTONASE (EC 3.1.1.31) (6PGL)].  
[Source:SWISSPROT;Acc:O95479]http://genomebiology.com/2004/6/1/R2 Genome Biology 2004,     Volume 6, Issue 1, Article R2       Romero et al. R2.3
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Genome Biology 2004, 6:R2
Table 2 shows statistics from version 7.5 of HumanCyc
(released in August 2003), after manual refinement of the
PGDB was completed. The 2,742 enzyme genes in HumanCyc
correspond to 9.5% of the human genome, and can be subdi-
vided into 1,653 metabolic enzymes, plus 1,089 nonmetabolic
enzymes (including enzymes whose substrates are macromol-
ecules, such as protein kinases and DNA polymerases). Our
best estimate of the total number of human metabolic
enzymes is the sum of the 1,653 known enzymes plus the 203
pathway holes, for a total of approximately 6.5% of the human
genome allocated to small-molecule metabolism (compared
to 16% of the E. coli genome). Of the 1,653 metabolic
enzymes, 622 are assigned to a pathway in HumanCyc, and
the remainder are not assigned to any pathway; we expect
that in the future some of the latter group of enzymes will be
assigned to some known human pathways not yet in Human-
Cyc, and to some human pathways that remain to be discov-
ered. Of the metabolic enzymes, 343 are multifunctional. The
number of enzymes is less than the number of enzyme genes
because, in many cases, the products of multiple genes are
required to form one active enzyme complex.
Table 3 shows all pathways present in HumanCyc, arranged
according to the MetaCyc pathway taxonomy. Only the top
two levels in the taxonomy are shown for the sake of brevity.
The 135 metabolic pathways in HumanCyc is a lower bound
on the total number of human metabolic pathways; this
number excludes the 10 HumanCyc superpathways that are
defined as linked clusters of pathways. The average length of
HumanCyc pathways is 5.4 reaction steps. Example Human-
Cyc pathways are shown in Figures 2 and 3. All HumanCyc
pathways can be accessed online from the HumanCyc Path-
ways page [8].
HumanCyc 7.5 contains 1,093 biochemical reactions, 896 of
which have been assigned to one or more of the 2,709
enzymes in HumanCyc. There are more enzymes than reac-
tions because of the existence of isozymes in the human
genome. This leaves 203 reactions that have no assigned
enzyme. These reactions correspond to the above-mentioned
pathway holes for the HumanCyc pathways. Of the 896 reac-
tions that have assigned enzymes, 428 have multiple iso-
zymes assigned.
Filling holes in HumanCyc pathways
The PathoLogic-based analysis of the annotated human
genome inferred 135 metabolic pathways. A total of 203 path-
way holes (missing enzymes) were present across 99 of these
pathways; that is, 38 pathways were complete. Using our
hole-filling algorithm [9], no candidate enzymes were found
for 115 of the 203 pathway holes. For the remaining 88 path-
way holes, candidates were obtained and evaluated. In 25 of
these 88 cases putative enzymes were identified with
sufficiently strong support that the enzyme and pathway
annotations within HumanCyc have been updated to reflect
these findings. See the HumanCyc release note history [10]
for a list of these 25 hole fillers added to HumanCyc version
7.6.
The original annotations of the human proteins that were
identified as candidate hole fillers fell into several classes: A
description of each class is presented below, with examples
included for some.
Table 1
The number of human proteins that were assigned enzyme activ-
ities (which caused them to become connected to reaction 
objects within HumanCyc), according to the mechanism of reac-
tion matching
Type of match Number of proteins
PathoLogic matched by EC 
number
2,057
PathoLogic matched by name 314
Ambiguous 27
Unmatched by PathoLogic 27,185
Probable enzymes 1,320
Manually matched 625
Table 2
HumanCyc statistics
PGDB objects Quantity
Replicons 76
Genes 28,783
Protein genes 28,583
Enzyme genes 2,742
RNA genes 200
tRNAs 50
Compounds 661
Polypeptides 28,602
Protein complexes 22
Enzymes 2,709
Enzymatic Reactions 1,093
With enzyme in HumanCyc 896
Pathways 135
Database links 389,262
Citations 41,810R2.4 Genome Biology 2004,     Volume 6, Issue 1, Article R2       Romero et al. http://genomebiology.com/2004/6/1/R2
Genome Biology 2004, 6:R2
Table 3
The entire set of pathways in HumanCyc, grouped by classes using the MetaCyc pathway classification hierarchy
Class Subclass Pathway EcoCyc AraCyc
Biosynthesis Polyamines Betaine biosynthesis * *
Betaine biosynthesis II
Spermine biosynthesis *
Polyamine biosynthesis II
Ornithine spermine biosynthesis *
Polyamine biosynthesis * *
UDP-N-acetylgalactosamine biosynthesis *
UDP-N-acetylglucosamine biosynthesis *
Nucleotides De novo biosynthesis of purine nucleotides *
Purine and pyrimidine metabolism
Purine biosynthesis 2
De novo biosynthesis of pyrimidine ribonucleotides *
Salvage pathways of pyrimidine ribonucleotides *
De novo biosynthesis of pyrimidine deoxyribonucleotides *
Salvage pathways of pyrimidine deoxyribonucleotides *
Fatty acids and lipids Fatty acid elongation - saturated * *
Fatty acid biosynthesis - initial steps * *
Phospholipid biosynthesis * *
Phospholipid biosynthesis II
Mevalonate pathway *
Triacylglycerol biosynthesis *
Cofactors, prosthetic groups, electron carriers Heme biosynthesis II
NAD biosynthesis II
NAD biosynthesis III
NAD phosphorylation and dephosphorylation *
Pyridine nucleotide biosynthesis * *
Pyridine nucleotide cycling *
Glutathione-glutaredoxin redox reactions *
Glutathione biosynthesis * *
Thioredoxin pathway * *
Pantothenate and coenzyme A biosynthesis * *
Pyridoxal 5'-phosphate salvage pathway * *
FormylTHF biosynthesis * *
Polyisoprenoid biosynthesis * *
Methyl-donor molecule biosynthesis *
Cell structures Colanic acid building blocks biosynthesis * *
GDP-mannose metabolism * *
Mannosyl-chito-dolichol biosynthesis *
UDP-N-acetylglucosamine biosynthesis *
Carbohydrates GDP-D-rhamnose biosynthesis
Gluconeogenesis * *
Mannosyl-chito-dolichol biosynthesis *
Trehalose degradation - low osmolarity * *
Aminoacyl-tRNAs tRNA charging pathway * *
Amino acid biosynthesis Alanine biosynthesis II *
Arginine biosynthesis 4 *
Citrulline biosynthesis
Asparagine biosynthesis I
Aspartate biosynthesis II
Cysteine biosynthesis II
Glutamate biosynthesis II *
Glutamine biosynthesis II
Glycine cleavage *
Glycine biosynthesis I * *http://genomebiology.com/2004/6/1/R2 Genome Biology 2004,     Volume 6, Issue 1, Article R2       Romero et al. R2.5
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Methionine salvage pathway
Proline biosynthesis I * *
Serine biosynthesis * *
Tyrosine biosynthesis II
Degradation Sugars and polysaccharides Lactose degradation 4 *
Lactose degradation 2 *
Sucrose degradation III
Galactose metabolism * *
Glucose 1-phosphate metabolism * *
Glycogen degradation * *
Mannose degradation *
Non-phosphorylated glucose degradation *
UDP-glucose conversion *
Ribose degradation * *
Trehalose degradation - low osmolarity * *
Sugar derivatives Lactate oxidation
Mannitol degradation *
Sorbitol degradation *
Glucosamine catabolism *
Other degradation Removal of superoxide radicals * *
Methylglyoxal degradation
Nucleosides and nucleotides (Deoxy)ribose phosphate metabolism * *
Periplasmic NAD degradation
Fatty acids Fatty acid oxidation pathway * *
Triacylglycerol degradation *
Lipases pathway *
Carboxylates, other Propionate metabolism - methylmalonyl pathway *
2-Oxobutyrate degradation
Acetate degradation * *
Pyruvate metabolism
N-acetylneuraminate degradation
C1 compounds Carbon monoxide dehydrogenase pathway *
Serine-isocitrate lyase pathway *
Amino acids, amines Alanine degradation 3 *
Arginine degradation III
Arginase degradation pathway
Arginine proline degradation *
Asparagine degradation 1 *
Aspartate degradation 1
Malate/aspartate shuttle pathway
L-cysteine degradation IV *
L-cysteine degradation VI
Cysteine degradation I
Glutamate degradation I *
Glutamate degradation IV
Glutamate degradation VII *
Glutamine degradation 1
Glutamine degradation II
Glycine degradation II
Glycine degradation I
Histidine degradation III
Histidine degradation I
Homocysteine degradation I
Isoleucine degradation I *
Isoleucine degradation III
Table 3 (Continued)
The entire set of pathways in HumanCyc, grouped by classes using the MetaCyc pathway classification hierarchyR2.6 Genome Biology 2004,     Volume 6, Issue 1, Article R2       Romero et al. http://genomebiology.com/2004/6/1/R2
Genome Biology 2004, 6:R2
Open reading frames (ORFs) with no assigned function (6 
candidates)
Putative enzymes were identified, for example, for the N-
acetylneuraminate lyase (LocusLink ID 80896), aldose 1-epi-
merase (LocusLink ID 130589) and imidazolonepropionase
(LocusLink ID 144193) reactions. In each of these cases, the
function of the protein was previously unknown.
Proteins assigned a nonspecific function (7 candidates)
The pathway hole filler assigned an enzyme previously anno-
tated with a general function. For example, 'amine oxidase
(flavin-containing) B' (LocusLink ID 4129), was assigned to a
more specific reaction, putrescine oxidase. A 'fatty acid syn-
thase' (LocusLink ID 54995) was identified to fill the 3-oxoa-
cyl-ACP synthase reaction.
Proteins assigned a single function but which our analysis indicates 
are multifunctional (9 candidates)
In these cases the program is postulating an additional func-
tion for a gene that already has an assigned function. The
pathway hole filler identified the enoyl-CoA hydratase
enzyme (LocusLink ID 1892) as a potential hole filler for the
3-hydroxybutyryl-CoA dehydratase reaction in the lysine
degradation and tryptophan degradation pathways. The dihy-
drofolate synthase hole in formylTHF biosynthesis was filled
by the enzyme (LocusLink ID 2356) catalyzing the folylpoly-
glutamate synthase reaction.
Leucine degradation II
Leucine degradation I *
Lysine degradation I *
Methionine degradation 1 *
4-Hydroxyproline degradation *
S-adenosylhomocysteine degradation
Phenylalanine degradation I
Proline degradation III
Proline degradation II
L-serine degradation * *
Threonine degradation 2
Tryptophan degradation I
Tryptophan degradation III *
Tryptophan kynurenine degradation
Tyrosine degradation
Valine degradation I *
Alcohols Aerobic glycerol degradation II *
Glycerol metabolism * *
Glycerol degradation I *
Ethanol degradation *
Amines and polyamines, other Citrulline degradation
N-acetylglucosamine, N-acetylmannosamine and N-
acetylneuraminic acid dissimilation
**
Glucosamine catabolism *
Energy metabolism Glycolysis 3 *
Glycolysis * *
Glycolysis 2
Glyceraldehyde 3-phosphate degradation *
Non-oxidative branch of the pentose phosphate pathway * *
Oxidative branch of the pentose phosphate pathway * *
Aerobic respiration - electron donors reaction list *
Pyruvate dehydrogenase * *
TCA cycle - aerobic respiration * *
Entner-Doudoroff pathway *
More detailed subclasses were not included for brevity. An asterisk in one of the last two columns means that the pathway is also present in the 
EcoCyc (E. coli) and/or AraCyc (A. thaliana) databases, respectively. Note that pathway names are derived from the MetaCyc database, which explains 
why HumanCyc contains a pathway called 'Heme Biosynthesis II' but not 'Heme Biosynthesis I.'
Table 3 (Continued)
The entire set of pathways in HumanCyc, grouped by classes using the MetaCyc pathway classification hierarchyhttp://genomebiology.com/2004/6/1/R2 Genome Biology 2004,     Volume 6, Issue 1, Article R2       Romero et al. R2.7
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Figure 2 (see legend on next page)
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(FLAVIN-CONTAINING) B:
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4-AMINOBUTYRATE
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MITOCHONDRIAL PRECURSOR:
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ALDH9A1
1.2.1.16
NAD
NH3
NH3
NH3
ALDH5A1
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3.5.1.53
MAOB
H2O
H2O2
H2O
H2O
NAD
H2O
NADP
H2O
H2O
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1.2.1.24
1.2.1.19
ALDEHYDE DEHYDROGENASE,
E3 ISOZYME:
L-glutamate
agmatine
4.1.1.19
SUCCINATE SEMIALDEHYDE
DEHYDROGENASE,
MITOCHONDRIAL PRECURSOR:
H. sapiens Pathway: arginine degradation III
Locations of Mapped Genes:R2.8 Genome Biology 2004,     Volume 6, Issue 1, Article R2       Romero et al. http://genomebiology.com/2004/6/1/R2
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Proteins that may have been assigned an incorrect specific function
Although our analyses of other pathway/genome databases
have revealed examples we consider to have been assigned an
incorrect function in the original annotation, our analysis of
the 25 HumanCyc pathway holes that we filled revealed no
candidates in this category.
The pathway hole filler not only identifies candidate proteins
for each pathway hole, but also determines the probability
that each candidate has the desired function. Table 4 displays
the homology-based features used by the pathway hole filler
to compute this probability. The table shows three example
reactions, each with two candidate enzymes and the data
gathered for each. The columns in the table display the com-
puted probability that the candidate has the desired function;
the number of query sequences that hit the candidate
(number of hits); the E-value for the best alignment between
the candidate and a query sequence (best E-value); the aver-
age rank of the candidate in the lists of BLAST hits; and the
average percentage of each query sequence that aligns with
the candidate.
In the first example, 28 imidazolonepropionase sequences
from other organisms were retrieved from Swiss-Prot and the
Protein Information Resource (PIR). Using BLAST, each
sequence was used to query the human genome for candidate
enzymes. Protein A was found in all of the 28 lists of BLAST
hits. From the numbers in the table, it is fairly obvious that
protein A is more likely to catalyze the imidazolonepropio-
nase reaction than is protein B. In the second example, given
the best E-value (1e-110) it is again not surprising that the
computed probability that protein C has N-acetylglu-
cosamine-6-phosphate deacetylase activity approaches 1.0.
In the last example, both proteins have excellent BLAST E-
values; in fact, the E-value for protein F indicates a better
match with the query sequences than the E-value for protein
E. In this case, protein E is found in 19 lists of BLAST hits ver-
sus four for protein F, and on average aligns with a much
larger fraction of each query sequence. When examined in
more detail, we discover that the four query sequences that
identified candidate F in their BLAST output are multifunc-
tional proteins with both aldose-1-epimerase activity and
UDP-glucose 4-epimerase activity. Protein F aligns with the
amino-terminal region of each of the four query sequences,
and has no detected similarity in the carboxy-terminal
regions. The UDP-glucose 4-epimerase activity lies in the
amino-terminal region of each multifunctional query protein.
Nutritional analysis of the human metabolic network
Nutritional requirements and their genetic and biochemical
basis are thought to have evolved principally in prokaryotes,
over billions of years [11]. Specific nutritional challenges have
driven the evolution of metabolic pathways and the
functional capabilities mediated by them. Indeed, eukaryotic
life acquired the basic building blocks of metabolism, that is,
sets of genes encoding enzymes that mediate specific meta-
bolic pathways, from prokaryotic ancestors. One may define a
metabolic pathway as a conserved set of genes that endow an
organism with specific nutritional/metabolic capabilities, for
example, the ability to grow in the absence of phenylalanine
because of the ability to synthesize phenylalanine.
Current knowledge of human nutrition based on metabolic
pathways is derived from various sources. One is clinical
observation of inherited human metabolic diseases and nutri-
ent deficiency states. For some pathways, like oxidative phos-
phorylation and the TCA cycle, direct studies of human
tissues, such as human muscle biopsies, have been made.
Nuclear magnetic resonance (NMR) has been used directly on
humans to study aspects of carbohydrate and energy metabo-
lism. Stable isotopes have been used to trace human metabo-
lism, from which inferences about nutrition have been made.
Dietary studies have been made in experimental mammals
such as rats and mice and metabolic pathways experimentally
elucidated in model organisms.
H e r e  w e  c o m p a r e  p r e v i o u s l y  accepted human nutritional
requirements with pathways derived from the human
genome to evaluate their agreement. For example, biosyn-
thetic pathways for essential human nutrients, that is, sub-
stances that must be provided in the diet such as the essential
amino acids and vitamins, would not be expected to occur in
the human genome.
Integration of human genome data with clinical, biochemical,
physiological and other data obtained both directly from
humans and indirectly from model organisms should, over
time, lead to a deeper understanding of human metabolism
and its nutritional implications in health and disease. When
the genome sequences of individuals are available, it may be
possible to address questions about the variation in optimal
Predicted HumanCyc pathway for arginine degradation Figure 2 (see previous page)
Predicted HumanCyc pathway for arginine degradation. The computer icon in the upper-right corner indicates this pathway was predicted 
computationally. Neither enzyme names nor gene names are drawn adjacent to the first three reactions of this pathway to indicate that these steps are 
pathway holes, meaning no enzyme has been identified for these steps in the human genome. The graphic at the bottom indicates the positions of genes 
within this pathways on the human chromosomes. Moving the mouse over a gene in the webpage for this diagram will identify the gene and the 
chromosome.http://genomebiology.com/2004/6/1/R2 Genome Biology 2004,     Volume 6, Issue 1, Article R2       Romero et al. R2.9
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Figure 3 (see legend on next page)
1.1.1.-
acetate
6.2.1.13
acetyl-CoA
phosphate
ADP
alcohol dehydrogenase 2:
aldehyde dehydrogenase 2 
NADH NAD NADH
ACAS2 acetyl coenzyme-A synthetase:
ATP
coenzyme A
acetaldehyde
NAD
ethanol
ADH1B
H. sapiens Pathway: oxidative ethanol degradation I
Locations of Mapped Genes:
 Superclasses:  Pathways
 Created by:  wagg  on  16-Sep-2003
 Comment: 
                              This ethanol degradation pathway begins with conversion of ethanol to acetaldehyde by cytosolic alcohol
                              dehydrogenase.   The resulting acetaldehyde passes into the mitochondrial compartment where it is converted to
                              acetate (by  mitochondrial aldehyde dehydrogenase).  Should acetate be activated to acetyl-CoA within the liver, it
                              would not  be oxidized by the Krebs cycle because of the prevailing high ratio of NADH + H / NAD+ within the
                              liver mitochondrial matrix.  Consequently, acetate leaves the mitochondrial compartment and the hepatocyte to be
                              metabolised by  extra-hepatic tissues  [Salway] .   Extrahepatic tissues take up acetate where it is converted to
                              acetyl-CoA  [Yamashita01] .
                              
                              Four distinct human ethanol degradation pathways have been described - three oxidative pathways and one
                              nonoxidative pathway.  All oxidative pathways mediate the oxidation of ethanol to  acetaldehye which is then
                              oxidized to acetate for subsequent extra-hepatic activation to  acetyl-CoA  [Yamashita01] .  Oxidative pathways
                              are differentiated based on the enzyme/mechanism  by which ethanol is oxidized to acetaldehyde.  The present
                              pathway utilizes cytoplasmic alcohol  dehydrogenase with the other two oxidative pathways utilizing endoplasmic
                              reticulum Microsomal  Ethanol Oxidizing System (MEOS) and peroxisomal catalase, respectively.  MEOS is also
                              known as  Cytochrome P450 2E1.  The nonoxidative pathway is less well characterized but produces fatty acid 
                              ethyl esters (FAEEs) as primary end products  [Best03] .  
                              
                              Oxidative and nonoxidative pathways have been demonstrated in a range of tissues including gastric, pancreatic,
                              hepatic and lung. Inhibition of oxidative ethanol degradation pathways raises both hepatic  and pancreatic FAEE
                              levels demonstrating that oxidative and nonoxidative pathways are alternative metabolically linked pathways.
                              Pancreatic ethanol metabolism occurs predominantly by the nonoxidative pathway  but oxidative routes to
                              acetaldehyde have also been demonstrated in the  pancreas - the cytochrome P450 2E1 & alcohol dehydrogenase
                              pathways  [Chrostek03] .
 References
  Best03:  Best CA, Laposata M (2003). "Fatty acid ethyl esters: toxic non-oxidative metabolites of ethanol and markers of ethanol
                  intake." Front Biosci 8;e202-17. PMID: 12456329
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  Salway:  Salway, J.G. "Metabolism at a Glance, Second Edition." p.90.
  Yamashita01:  Yamashita H, Kaneyuki T, Tagawa K (2001). "Production of acetate in the liver and its utilization in peripheral
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nutrition from person to person. Explicit identification of
specific areas of inconsistency will serve to focus ongoing
experimental efforts to elucidate the molecular basis of
human nutrition and metabolism.
For all of the nine amino acids essential for humans, Patho-
Logic did not predict the presence of a corresponding biosyn-
thetic pathway (see Table 5) [12]. And for all of the 11
nonessential amino acids, PathoLogic did predict the pres-
ence of a corresponding biosynthetic pathway. For 12 of 13
essential human vitamins, PathoLogic did not predict the
presence of a corresponding metabolic pathway (note that
PathoLogic could not have predicted such a pathway for six of
those vitamins because MetaCyc does not contain such a
pathway). PathoLogic did predict the presence of a pathway
called 'pantothenate and coenzyme A biosynthesis pathway',
which is not expected given that pantothenate is an essential
human nutrient. However, examination of the predicted
pathway reveals that no enzymes in the first part of the path-
way (biosynthesis of pantothenate) are present; all enzymes
are in the portion of the pathway that synthesizes coenzyme A
from pantothenate. Thus, this false-positive prediction can be
attributed to the fact that MetaCyc does not draw a boundary
b e t w e e n  w h a t  s h o u l d  p r o b a b l y  b e  c o n s i d e r e d  t w o  d i s t i n c t
pathways. No hard-and-fast rules are generally accepted as to
how to draw boundaries between metabolic pathways; there-
fore the PathoLogic method cannot produce objective and
well accepted pathway boundaries (nor can any other known
algorithm).
Comparative analysis of the metabolic networks of 
human, E. coli and Arabidopsis
Table 6 indicates whether or not each HumanCyc pathway is
present in the EcoCyc E. coli PGDB and in the AraCyc PGDB
for  A. thaliana [13]. More precisely, we say a pathway is
shared among multiple PGDBs if the same MetaCyc pathway
has been predicted to be present in each PGDB; that is, if the
pathway has exactly the same set of reactions in the PGDBs
(the unique identifier of the MetaCyc pathway is reused in any
PGDB to which the pathway is copied). The comparison does
not consider how many pathway holes are in the PGDBs, but
relies on the PathoLogic prediction (plus subsequent manual
review) that the pathway is present; that is, if PathoLogic
determines that the pathway is present despite its holes, the
comparison considers it to be present. Note that we do not
count the presence of related pathway variants; that is, if
organism A contains pathway P and organism B contains a
variant of P, we do not score this case as a shared pathway.
Some shared pathways will include pathway holes.
Figure 4 shows how the three metabolic networks intersect by
means of a Venn diagram, depicting each PGDB's pathway
complement as a circle. The number within a given intersect-
ing area denotes the number of pathways shared by the corre-
sponding combination of PGDBs. For example, HumanCyc
has 55 pathways in common with EcoCyc, as well as 67 with
AraCyc, while EcoCyc and AraCyc share 69 pathways. Thirty-
five pathways are common to all three databases, and are
shown in Table 6. The 35 pathways include significant num-
Curated HumanCyc pathway for oxidative ethanol degradation Figure 3 (see previous page)
Curated HumanCyc pathway for oxidative ethanol degradation. This pathway was not predicted by PathoLogic, but was entered into HumanCyc as part of 
our subsequent literature curation effort. The flask icon in the upper-right corner indicates this pathway is supported by experimental evidence. The 
complete comment for this pathway is available at [38]
Table 4
A comparison of candidates for three missing enzymes
Candidate P (has-
function)
Number of hits Best E-value Average rank Percentage of 
query aligned
Reaction hole: imidazolonepropionase
A ENSG00000139344-MONOMER Functional annotation: UNKNOWN 0.98 28 7.0e-69 1.0 91.9
B ENSG00000119125-MONOMER Functional annotation: Guanine 
deaminase
0.00018 6 3.0e-6 3.5 37.9
Reaction hole: N-acetylglucosamine-6-phosphate deacetylase
C ENSG00000162066-MONOMER Functional annotation:CGI-14 protein 0.998 9 1e-110 1.0 94.6
D ENSG00000119125-MONOMER Functional annotation: Guanine 
deaminase
1.0e-5 4 0.85 4.0 19.9
Reaction hole: aldose 1-epimerase
E ENSG00000143891-MONOMER Functional annotation:AMBIGUOUS 0.98 19 3e-74 1.58 81.9
F ENSG00000117308-MONOMER Functional annotation:UDP-glucose 4-
epimerase
0.93 4 1e-100 1.0 58.3http://genomebiology.com/2004/6/1/R2 Genome Biology 2004,     Volume 6, Issue 1, Article R2       Romero et al. R2.11
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bers of pathways from all the pathway classes (biosynthesis,
catabolism and energy metabolism), and constitute a signifi-
cant fraction of the pathway complements of both E. coli
(20.1% of the 174 pathways in EcoCyc) and H. sapiens (25.7%
of the 135 pathways in HumanCyc). Those 35 pathways there-
fore constitute a likely upper bound on the number of univer-
sally and exactly conserved metabolic pathways. It is an upper
bound in the sense that as more organisms are considered,
the list of universal pathways cannot grow larger.
We propose that the cofactor biosynthesis pathways shared
among all three organisms have been conserved because first,
they produce complex molecules that are not available from
the environments of these organisms; second, these mole-
cules are used as cofactors in so many reactions within the
metabolic networks that the requirement for them is abso-
lute; and third, no other pathway to accomplish the synthesis
of that molecule has evolved. A study by Ouzounis and Karp
surveyed global properties of the E. coli metabolic network,
including the most frequently used substrates and cofactors
[14]. Together, the two pyridine nucleotides NAD and NADP
are the third most common substrate in the E. coli metabolic
network (after water and ATP): removing the ability to syn-
thesize NAD would disable so many reactions as to be insur-
mountable. Pyridoxal-5'-phosphate is the second most
common cofactor (after Mg2+). Coenzyme A and acetyl-CoA
together constitute the seventh most common substrate in E.
coli, formylTHF constitutes the 23rd most common
substrate, and thioredoxin and glutathione constitute the
40th and 41st most common substrates.
Discussion
Pathway variants
The level of metabolic pathway variation in the biosphere
remains to be determined. Metabolic pathways have been
experimentally elucidated in a small number of model
prokaryotic and eukaryotic organisms. Despite the relatively
small number of carefully studied organisms, significant
pathway variation has been observed both between distinct
organisms and within a given organism. For example, at least
four variants of the 'glycolytic pathway' have been described
[15]. Sets of variant pathways for glycolysis [16], leucine deg-
radation [17], and NAD biosynthesis [18] can be viewed
through the MetaCyc website. In MetaCyc, variant pathways
are named with roman numerals; for example, 'NAD biosyn-
thesis I' and 'NAD biosynthesis II'.
M e t a b o l i c  p a t h w a y s  a p p e a r  t o  h a v e  d i v e r g e d  i n  a  m a n n e r
analogous to the divergence of biological sequences. The
demonstrated existence of pathway variants and ongoing
uncertainty as to the full extent of such variation has signifi-
cant implications for ongoing efforts to predict biochemical
pathways from incomplete genomic data. First, it means that
the precision with which we can infer pathways in one organ-
ism from another solely on the basis of genomic data remains
to be determined, because when genomic evidence is found in
organism Ok for the presence of a pathway, Pj, that was
experimentally elucidated in an organism Oj, this alone does
not constitute conclusive evidence for the presence of Pj in Ok,
since a variant of Pj (Pk) may be present in Ok (note that any
such Pk variant may not even have been experimentally char-
acterized). Second, for those pathways with known closely
related variants (for example, two pathways differing by only
a single step with one step differing from the other only at the
level of co-reactants/products, such as one using NADP/
NADPH the other using NAD/NADH as cosubstrates/prod-
ucts) it is often impossible to choose among these variants on
the sole basis of genomic data because of the limited resolu-
tion of sequence analysis.
Table 5
Comparison of known essential human nutrients with corre-
sponding biosynthetic pathways in MetaCyc and in HumanCyc
Essential nutrient in 
humans
Biosynthetic pathway 
in MetaCyc?
Biosynthetic pathway 
inferred in humans?
Amino acids
Arginine Y N
Histidine Y N
Isoleucine Y N
Leucine Y N
Lysine Y N
Methionine Y N
Phenylalanine Y N
Threonine Y N
Valine Y N
Vitamins
Ascorbic acid (Vitamin 
C)
YN
Biotin (Vitamin H) Y N
Folic acid (Vitamin M) Y N
Niacin (Vitamin B3)N N
Pantothenic acid Y Y
Pyridoxine (Vitamin 
B6)
NN
Riboflavin (Vitamin B2)Y N
Thiamine (Vitamin B1)Y N
Cobalamin (Vitamin 
B12)
YN
Retinol (Vitamin A) N N
Vitamin D N N
Tocopherol (Vitamin 
E)
NN
Vitamin K N N
Note that a pathway cannot be predicted in HumanCyc if it does not 
exist in MetaCyc.R2.12 Genome Biology 2004,     Volume 6, Issue 1, Article R2       Romero et al. http://genomebiology.com/2004/6/1/R2
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We have developed a general approach to representing the
presence of pathway variants. MetaCyc pathways (approxi-
mately 500) have been grouped using a function-based clas-
sification system. Each grouping defines a 'pathway family',
each member of which (a pathway variant) endows an organ-
ism with one or more specific functional capabilities, for
example, the ability to grow in the absence of phenylalanine.
Within a given pathway family, variants may be clustered into
one or more subfamilies. Subfamilies are groups of pathways
that show significant overlap/similarity in terms of individual
reaction steps (reactants and products of each reaction);
enzymatic activities that catalyze these steps; and genes
encoding the enzymes that mediate these activities
Table 6
Pathways (including superpathways) that are common to human, bacteria and plant PGDBs
Class Subclass Pathway
Biosynthesis Polyamines Betaine biosynthesis
Polyamine biosynthesis
Fatty acids and lipids Phospholipid biosynthesis
Fatty acid biosynthesis - initial steps
Fatty acid elongation - saturated
Cofactors, prosthetic groups, electron carriers Pyridine nucleotide biosynthesis
Thioredoxin pathway
Glutathione biosynthesis
Pantothenate and coenzyme A biosynthesis
Pyridoxal 5'-phosphate salvage pathway
Polyisoprenoid biosynthesis
FormylTHF biosynthesis
Cell structures Colanic acid building blocks biosynthesis
GDP-mannose metabolism
Carbohydrates Gluconeogenesis
Trehalose degradation - low osmolarity
Aminoacyl-tRNAs tRNA charging pathway
Amino acid biosynthesis Proline biosynthesis I
Glycine biosynthesis I
Serine biosynthesis
Degradation Sugars and polysaccharides Glucose 1-phosphate metabolism
Galactose metabolism
Trehalose degradation - low osmolarity
Glycogen degradation
Ribose degradation
Other degradation Removal of superoxide radicals
Nucleosides and nucleotides (Deoxy)ribose phosphate metabolism
Fatty acids Fatty acid oxidation pathway
Carboxylates, other Acetate degradation
Amino acids, amines L-serine degradation
Alcohols Glycerol metabolism
Energy metabolism Pyruvate dehydrogenase
TCA cycle - aerobic respiration
Glycolysis
Oxidative branch of the pentose phosphate pathway
Nonoxidative branch of the pentose phosphate pathway
HumanCyc, H. sapiens; EcoCyc, E. coli; AraCyc, A. thaliana. The pathways in the table are included in all three PGDBs.http://genomebiology.com/2004/6/1/R2 Genome Biology 2004,     Volume 6, Issue 1, Article R2       Romero et al. R2.13
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The similarity between variants within a given subfamily sug-
gests they evolved from a common ancestor pathway. For
example, at least four variants of the glycolytic pathway have
been described; all enable the conversion of glucose to pyru-
vate and show significant overlap/similarity in their compo-
nent reactions. Other pathway variants have been observed
that show little similarity to each other (for example, some of
the amino-acid degradation pathways) and these are there-
fore believed to have evolved from distinct ancestor path-
ways. The existence of pathway subfamilies indicates that
multiple pathways have coevolved to meet common nutri-
tional/metabolic challenges.
For the purposes of this paper, genomic evidence for the pres-
ence of a specific biochemical pathway, P1, in humans is taken
as evidence that P1 and/or other members of the pathway
family to which P1 belongs are likely to be present in humans
(including those not yet included in MetaCyc and/or experi-
mentally elucidated). Indeed, PathoLogic sometimes inferred
the presence of multiple variant pathways in humans. This
occurred because when evidence was found in the genome for
the presence of one member of a pathway family/subfamily,
this evidence often also supported the presence of other
members of this family/subfamily. In these cases, all inferred
variants were included in HumanCyc. Of course, the specific
members of a given pathway family actually present in
humans may include one or more of those inferred from Met-
aCyc or other members of this pathway family not yet
described in MetaCyc and/or not yet experimentally
elucidated from any organism. It is attractive to think that
multiple variant pathways might refer to metabolically differ-
entiated tissues in the body, or to different regulatory states
available to the same tissue. An example of the latter would be
the liver; at different times of day it either synthesizes glyco-
gen, taking glucose from the blood, or it degrades glycogen to
maintain the blood glucose level.
HumanCyc as a tool
The HumanCyc PGDB is freely available for use by the scien-
tific community from the SRI website [19]. Basic queries to
HumanCyc can be issued through the BioCyc Query Page
[20]. This page supports a number of query types. For text
searches through the DB, for example, enter 'tryptophan' next
to the 'Query All (by name)' box, and then click 'submit' to
retrieve a list of all enzymes, pathways, compounds, and reac-
tions whose name includes that word. Click on 'Choose from
a list of pathways' to generate a list of all pathways within
HumanCyc. Click 'submit' near 'Browse Ontology' to browse
one of several possible classification hierarchies, such as the
ontology that classifies metabolic pathways according to their
physiological role.
When viewing a HumanCyc pathway display, be aware that
the software omits enzyme names for pathway holes. That is,
when no human protein has been identified that catalyzes a
reaction within a pathway, no enzyme name is drawn next to
that reaction.
The cellular overview [21], a full human metabolic pathway
map, provides a tool for analysis of high-throughput datasets.
The Omics Viewer [22] allows the user to visualize gene-
expression data, protein-expression data, metabolomics
measurements, or reaction flux data in a pathway context by
painting reaction steps in the metabolic overview with colors
that represent the expression levels of the genes coding for
enzymes that catalyze those steps.
The PathoLogic summary page for H. sapiens includes a
report that lists the evidence for each predicted pathway in
HumanCyc, with pathways sorted according to the MetaCyc
pathway ontology [23].
HumanCyc is currently available for local installation at your
institution [24] as a set of flat files, and as part of an executa-
ble program running on Windows/Intel, Linux/Intel and
Solaris/Sun. The latter configuration can function as both a
desktop application, and as a local mirror of the HumanCyc
website on the user's intranet.
Numbers of pathways, including superpathways, shared by the three  PGDBs HumanCyc (H. sapiens), EcoCyc (E. coli), and AraCyc (A. thaliana) Figure 4
Numbers of pathways, including superpathways, shared by the three 
PGDBs HumanCyc (H. sapiens), EcoCyc (E. coli), and AraCyc (A. thaliana). 
The numbers outside the circles represent the total number of pathways 
in the corresponding PGDB. The numbers inside the intersecting areas 
represent the number of pathways that fall into each area. For example, 
there are 55 pathways in common between HumanCyc and EcoCyc (20 + 
35). AraCyc contains 177 total pathways: 76 that are unique to A. thaliana, 
and 101 that are shared with other organisms.
HumanCyc EcoCyc
174
85 20 48
135
35
34 32
76
177
AraCycR2.14 Genome Biology 2004,     Volume 6, Issue 1, Article R2       Romero et al. http://genomebiology.com/2004/6/1/R2
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Related work
Related databases of human metabolic pathways include the
GenMAPP [25] collection of 14 drawings of human metabolic
pathways that are available through the web; the KEGG [26]
metabolic pathway website, which allows coloring of a set of
reference pathway maps to indicate which enzymatic steps
have corresponding human enzymes; and the Reactome
(Cold Spring Harbor Laboratory, European Bioinformatics
Institute (EBI) and the Gene Ontology (GO) Consortium)
project, which has curated human metabolic pathways in a
web-accessible database [27].
PathoLogic was the first program for automated inference of
genome-scale pathway reconstructions from genome data
[28]. Additional methods for prediction of metabolic path-
ways include methods that infer 'extreme pathways' and 'ele-
mentary modes' from flux-balance models of reaction
networks [29], which have been applied to the human mito-
chondrion [30]. Rather than recognizing known, historically
defined pathways in a large reaction network, as does Patho-
Logic, these methods infer pathways from the stoichiometric
matrix representing a biochemical network by convex analy-
sis. The biological utility and meaning of these pathways, and
their correspondence to known metabolic pathways that have
been established through experimental studies, remains to be
demonstrated. One benefit of pathway analysis by projecting
previously known pathways onto a genome using PathoLogic
is the fact that projection of known pathways tells us what
reactions to expect to occur in another organism, leading to
the identification of pathway holes, and the directed search
for their fillers. In fact, the occurrence of hundreds of pathway
holes in every genome we have analyzed raises the question of
how the extreme pathways method can work given that the
r e a c t i o n  n e t w o r k s  i t  r e l i e s  o n  m u s t  o m i t  h u n d r e d s  o f
reactions (the pathway holes) as a result of the incomplete-
ness of genome annotations.
The following additional pathway prediction methods are
related to this work, but have not been applied on a genome
scale and have received little validation. Zien and colleagues
use gene-expression data to score pathways that are enumer-
ated combinatorially from a reaction database. Van Helden
and colleagues use clustering of gene-expression data to gen-
erate seed reactions that are used to combinatorially enumer-
ate pathways [31,32]. McShan et al. infer novel
biotransformation rules for xenobiotics from the molecular
graphs of compounds [33]. A recent review discusses the
potential for reconstruction of metabolic networks using
metabolomics technology [34].
Limitations of HumanCyc and future work
The user of HumanCyc should be aware of several potential
limitations that influence the interpretation of the DB con-
tents. First, HumanCyc is incomplete in the sense that some
known (and unknown) human metabolic pathways are not
present in it. It will require a significant database curation
effort to enter all known pathways. Second, HumanCyc prob-
ably contains false-positive pathway predictions. Our
approach is to err on the side of being more inclusive in our
pathway predictions so that all potential pathways are
brought to the attention of the scientific community for eval-
uation. For example, HumanCyc sometimes contains
multiple pathway variants that we currently lack the evidence
to choose between, and in other cases the actual human path-
way may be a variant of the pathway present in HumanCyc.
Third, HumanCyc does not encode information about the
location (compartment(s), cell type(s) or tissue(s)) in which a
pathway occurs. Each pathway is defined using all identified
human enzymes, meaning that location-specific versions of a
pathway are not specifically identified. Furthermore, the
presence of a pathway could be incorrectly inferred because
the enzymes that make up a pathway are found in different
locations and are never expressed in a common location,
meaning that the pathway can never occur in its entirety.
Fourth, HumanCyc does not contain nucleotide or amino-
acid sequences. Our future work will address the first three of
these limitations, and will include a significant effort to man-
ually refine and update HumanCyc with pathway and enzyme
information from the biomedical literature. To date, three
pathways have been added to HumanCyc through manual
curation. Experimentally elucidated pathways in HumanCyc
will be annotated as such with evidence codes; pathways pre-
dicted by PathoLogic are annotated as computationally
inferred.
HumanCyc can be used to develop an agenda for experimen-
tal refinement of the human metabolic map. Predicted path-
ways should be experimentally verified, with particular
attention to choosing among multiple pathway variants. Can-
didate 'fillers' for the 178 unresolved pathway holes identified
herein should be identified.
Conclusions
PGDBs endow genomic information with an extended dimen-
sion that allows researchers to analyze an organism's genome
with respect to the causal relationships inherent to a meta-
bolic network. In this sense, HumanCyc provides the oppor-
tunity to look at human metabolic processes within the
context of the annotated human genome, and vice versa. The
computationally predicted metabolic network provided a
rational framework for understanding the genetic basis of
some well-characterized human dietary requirements, that is,
11 nonessential amino acids and 22 essential nutrients (9
essential amino-acids and 13 essential vitamins).
PathoLogic's pathway prediction process provides a reasona-
bly accurate picture of the metabolic network, and Pathway
Tools provides the user with extensive capabilities for refin-
ing the DB to reflect improvements in our understanding of
the human metabolic network. The query and visualization
capabilities of the Pathway Tools software (such as the visual-http://genomebiology.com/2004/6/1/R2 Genome Biology 2004,     Volume 6, Issue 1, Article R2       Romero et al. R2.15
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ization of gene-expression data superimposed on the meta-
bolic map) will facilitate novel approaches for analyzing the
complexity of functional relationships within the human
genome.
Materials and methods
Data gathering and preparation
The PathoLogic program generates a new PGDB starting
from the annotated genome of an organism, meaning a com-
plete genome sequence (closed or gapped) for which gene
prediction and sequence analyses have already identified the
locations of likely coding regions, and have predicted the
functions of these genes. We used Ensembl Build 31 as our
main data source for the annotated human genome, and com-
plemented that information with data from LocusLink, the
National Center of Biotechnology Information (NCBI) data-
base of genetic loci. We used GenBank as our source for the
mitochondrion genome, as this information was not included
in Ensembl. LocusLink mitochondrial loci were used to com-
plement this information when applicable.
The information from these different sources required special
preprocessing to make it available to PathoLogic. That pre-
processing addressed three needs: first, to convert the dispa-
rate data formats used by these sources into a format parsable
by PathoLogic; second, to extract information useful to Path-
oLogic; and third, to remove redundancy among the sources.
In the case of Ensembl, the standard Ensembl flat files
included just a subset of the information needed for the PGDB
generation process. We therefore used the EnsMart facility
provided by Ensembl [5] to generate files with the required
data. EnsMart allows the user to select subsets of the genome
(from small regions to entire chromosomes) and output
desired data about each gene in different tabular formats.
Additional data file 1 lists the genetic element files generated
using EnsMart. One file was generated for each human chro-
mosome and contig, with the file names corresponding to the
chromosome and contig names  i n  E n s e m b l .  W h e n  t h e
corresponding chromosome for a given contig was known,
the contig's file name would be constructed by prepending the
chromosome's name to the contig's name, otherwise 'Un', for
unknown, was prepended to the contig's name.
W e  s e l e c t e d  L o c u s L i n k  f i l e  L L 3 _ 0 3 0 3 1 9  ( V e r s i o n  f r o m  1 9
March, 2003), which contained all data required by Patho-
Logic (the LocusLink organism-specific files, like the
Ensembl files, did not include all the needed database fields).
Table 7 shows the types of information extracted from each
source when available. For example, we included a large
number of comments extracted from LocusLink in Human-
Cyc; each such comment in HumanCyc ends with a citation to
LocusLink to properly attribute its source. Function descrip-
tions for gene products are very important for PathoLogic, as
they will be matched against enzyme activity names stored in
MetaCyc, a multi-organism database of experimentally deter-
mined metabolic pathways and enzymes [15]. In Ensembl,
such functional information had to be parsed from the 'func-
tion' field in EnsMart data. This field sometimes includes long
and complex descriptions of the gene product's function,
mostly extracted by Ensembl from SwissProt [35]. These
descriptions could include synonyms, EC numbers, and mul-
tiple functions (see Figure 1). All that information had to be
extracted and presented to PathoLogic in a structured form.
When generating the input files for PathoLogic, information
from Ensembl and LocusLink was combined only when the
Ensembl record for a gene included a cross reference to a
LocusLink ID. In such a case, data from the LocusLink entry
was merged with that of the Ensembl gene, meaning that
when both databases provide an attribute such as a gene
Table 7
Information extracted from different data sources
Data source (version) Information extracted (for each gene or locus) Number of genes
Obtained Nonredundant
Ensembl (Build 31) Gene name, chromosome or contig, start and end positions, strand (transcription 
direction), exons, gene-product (including function name(s) or description(s), synonyms 
and EC number(s)), cross references (IDs) to other databases (SwissProt, HUGO, PDB, 
GO, RefSeq, OMIM, Entrez, SPTREMBL, EMBL, LocusLink).
24,847
LocusLink (03/29/2003) Gene name, chromosome, gene product (function name or description), function 
synonyms, EC number(s), gene and protein comments, cross references (IDs) to other 
databases (Entrez, UCSC Genome, RefSeq, GO, OMIM, UniGene, PubMed)
18,880 3,936
GenBank NC_001807 (mitochondrion) Gene name, start and end positions, transcription direction, gene product (function 
name or description)
35
Functional information in Ensembl had to be extensively parsed to extract multiple functions, EC numbers, and/or synonyms. The 'nonredundant' column shows the number of 
genes from LocusLink that had no corresponding gene in the other two data sources (Ensembl and GenBank).R2.16 Genome Biology 2004,     Volume 6, Issue 1, Article R2       Romero et al. http://genomebiology.com/2004/6/1/R2
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name, the Ensembl data is preferred. This approach created
gene objects for HumanCyc that include information from
both the Ensembl and the LocusLink entries. Those Human-
Cyc gene objects use the Ensembl ID as their unique identi-
fier, and have database links to the corresponding LocusLink
entries. For the mitochondrial data, the number of LocusLink
mitochondrial loci was small enough so that they were easily
checked for matches with corresponding genes in the Gen-
Bank files.
LocusLink loci that had no direct counterpart in either the
Ensembl data or the GenBank mitochondrial data (for exam-
ple, LocusLink loci that were not directly referenced in any
Ensembl gene record) were assigned their own record in the
PathoLogic input files. The LocusLink ID was used as the
unique identifier for these gene objects. Only loci correspond-
ing to 'real' genes (not models, phenotypes or pseudogenes)
were included in HumanCyc. We must point out that records
corresponding only to LocusLink loci lack gene position
information, so they cannot be precisely placed on a chromo-
some map. We were aware that adding these LocusLink-only-
based records to HumanCyc would produce some redun-
dancy in the database, but this was accepted for the sake of
completeness. Manual analysis of similar Ensembl and
LocusLink-based gene objects after building HumanCyc led
to the fusion of gene objects corresponding to the same gene.
The number of LocusLink gene objects that were not merged
to corresponding gene objects from Ensembl or GenBank is
shown in the 'nonredundant' column of Table 7.
It is readily apparent from Table 7 that HumanCyc, thanks to
the combination of the Ensembl and LocusLink data sources,
has excellent cross-reference coverage to many other biologi-
cal databases (including Ensembl and LocusLink them-
selves). In addition to the databases mentioned in Table 7, we
added links to the GeneCards genomic database for those
genes with known HUGO IDs.
Seventy-six PathoLogic input files were generated from the
preceding data sources: 24 for the human chromosomes, one
for the mitochondrion, 50 for the different contigs not yet
integrated to the chromosomal sequences, and one called
'unknown' for all the loci that had no chromosome informa-
tion. A replicon object was created in HumanCyc for each of
these files.
Prediction of human metabolic pathways using 
PathoLogic
This section summarizes the PathoLogic algorithm (for a
more detailed description of the method see [36,37]). For an
evaluation of the accuracy of PathoLogic see [36].
After initializing the schema of the new PGDB, a database
object is created for each replicon and contig, and for each
gene and its corresponding gene product. PathoLogic then
tries to determine the metabolic reaction catalyzed (if any) by
each gene product in the organism by using its EC number, if
provided in the annotation, and by matching the name of each
gene product against the extensive dictionary of enzyme
names within the MetaCyc DB [15]. Finally, the list of reac-
tions now known to be catalyzed by the organism is matched
against all the pathways in MetaCyc. For pathways with sig-
nificant numbers of matches (see [36] for a detailed descrip-
tion of this algorithm), PathoLogic imports the pathway and
its associated reactions and substrates from MetaCyc into the
new PGDB. This method of pathway prediction is analogous
to predicting the function of a protein based on sequence sim-
ilarity to a protein of known function, in that both methods
recognize the presence of something known (a known path-
way versus a known protein function) based on a similarity
between patterns (a pattern of enzymes present versus a
sequence pattern). The two methods share similar limita-
tions: just as sequence similarity cannot predict protein
functions that are not in the sequence database, PathoLogic
cannot predict pathways that are not in MetaCyc.
As mentioned above, PathoLogic will assign reactions for
those enzymes that have an exact EC number match or name
match against MetaCyc. A gene product name may not exactly
match that of any enzyme in MetaCyc. Some enzyme names
will produce ambiguous matches or no match at all. Patho-
Logic assembles a list of 'probable enzymes' that includes
both ambiguous matches and nonmatched proteins whose
names suggest enzymatic activity. This list is examined man-
ually through a PathoLogic module that helps the user
evaluate possible matching candidates within MetaCyc and
assign probable enzymes to the correct reaction, if possible.
An alternative to our strategy of using the existing EC number
and function assignments from LocusLink and Ensembl
would be for us to discard those assignments and to reanalyze
the genome using sequence analysis methods to produce new
assignments. We rejected this approach for two reasons: first,
it would discard some experimentally derived function
assignments in place of less reliable computational assign-
ments; and second, we consider the Ensembl function predic-
tions to be of high quality, and we are aware of no evidence
that our group, or any other group, has a sequence analysis
methodology that will produce function assignments that are
substantially more accurate than those of Ensembl.
Finally, PathoLogic generates reports summarizing the
a m o u n t  o f  e v i d e n c e  s u p p o r t i n g  e a c h  p a t h w a y  i n  t h e  n e w
PGDB, and listing the pathway holes, that is, the enzymes
missing from each predicted pathway. This information helps
the user identify pathways that should be deleted from the
PGDB, such as variant pathways and false-positive predic-
tions made by PathoLogic. For example, MetaCyc includes
eight variants of the TCA cycle. Several of these might appear
in a newly predicted PGDB. False-positive pathways, some of
which are predicted because they share reactions with other
pathways in MetaCyc, should be removed from the PGDB.http://genomebiology.com/2004/6/1/R2 Genome Biology 2004,     Volume 6, Issue 1, Article R2       Romero et al. R2.17
c
o
m
m
e
n
t
r
e
v
i
e
w
s
r
e
p
o
r
t
s
r
e
f
e
r
e
e
d
 
r
e
s
e
a
r
c
h
d
e
p
o
s
i
t
e
d
 
r
e
s
e
a
r
c
h
i
n
t
e
r
a
c
t
i
o
n
s
i
n
f
o
r
m
a
t
i
o
n
Genome Biology 2004, 6:R2
Once variant or false-positive pathways are eliminated by the
user, PGDB generation has been completed.
Filling holes in HumanCyc pathways
To determine the function of a protein sequence, researchers
typically use a single sequence to search for potential
homologs in a large public database. To identify sequences to
fill pathway holes, we have, in effect, reversed this search
process. We search the genome for a sequence that will pro-
vide the enzymatic function needed to fill each pathway hole.
Our method uses multiple isozyme sequences (retrieved via
MetaCyc from Swiss-Prot and PIR) to search a genome for
similar sequences (hole-filler candidates). We then evaluate
each candidate to determine the probability that the sequence
has the desired function based on homology and pathway-
based data. A hole-filler tool that implements this pathway-
driven gene-finding methodology has been developed [9].
Analysis of HumanCyc metabolic network
Once HumanCyc was built and manually refined, as
explained above, we examined the metabolic network within
HumanCyc in order to make a preliminary assessment of the
quality of PathoLogic's predictions and to check for pathways
not previously thought to occur in humans. We also com-
pared the metabolic network of HumanCyc to that of two of
our curated PGDBs, corresponding to a bacterium and a
plant. These PGDBs are EcoCyc (E. coli) and AraCyc (A.
thaliana).
Additional data files
The following additional data are available with the online
version of this article. Additional data file 1 contains a table
listing the data file names generated from EnsMart for each
human chromosome or contig and provided as input to Path-
oLogic, thus indicating which contigs are associated with
which chromosomes.
Additional data file 1 A table listing the data file names generated from EnsMart for each  human chromosome or contig and provided as input to PathoLogic,  thus indicating which contigs are associated with which  chromosomes A table listing the data file names generated from EnsMart for each  human chromosome or contig and provided as input to PathoLogic,  thus indicating which contigs are associated with which  chromosomes Click here for additional data file
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